Molecular analysis of leukemias with chromosomal translocation and its application for clinical Diagnosis
Molecular analysis of leukemias with chromosomal translocation and its application for clinical Diagnosis
批准号:
05454328
负责人:
HIRAI Hisamaru
金额:
$4.1万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for General Scientific Research (B)
财政年份:
1993
资助国家:
日本
项目状态:
已结题
起止时间:
1993 至 1994
中文摘要
T(3;21)(q26;q22)易位是慢性粒细胞白血病(CML)急变期中发现的一种持续的染色体异常,被认为在CML向急变期发展的过程中起着重要作用。位于急性髓细胞白血病t(8;21)(q22;q22)易位断裂点的AML1基因也被t(3;21)(q26;q22)易位重排。对携带t(3;21)的白血病细胞系细胞(SKH1)的cDNA文库进行筛选,分离到AML1/EVI-1嵌合cDNAs。SKH1细胞表达了180kD的AML1-EVI-1融合蛋白,该融合蛋白含有AML1的氨基末端半部分,包括一个矮小的同源结构域,与整个锌指EVI-1蛋白融合在一起。这些发现有力地表明t(3;21)易位导致了一类新的嵌合转录因子的形成,这可能与慢性粒细胞白血病…的进展有关。更多的是通过干扰细胞的生长和分化。生化分析表明,AML1/EVI-1本身不改变通过PEBP2位点的反式激活水平,但主要抑制完整的AML1的反式激活,AML1被认为是髓系细胞分化的刺激因子。DNA结合竞争是AML1/EVI-1这种显性负效应的一种可能机制,因为它以比AML1更高的亲和力与PEBP2结合。此外,AML1/EVI-1还能刺激c-fos启动子的反式激活,提高AP-1的活性。利用AML1/EVI-1的缺失突变体进行的实验表明,这两个功能是相互独立的,因为对完整AML1活性的主要负面影响和对AP-1活性的刺激分别依赖于C末端附近的矮小结构域和锌指结构域。此外,我们还发现AML1/EVI-1阻断了G-CSF诱导的32Dc13髓系细胞的粒细胞分化。也有人认为,融合蛋白的AML1和EVI-1来源的部分在这种分化阻断中发挥了关键作用。结论:t(3;21)白血病细胞转化可能是由于AML1/EVI-1嵌合蛋白的双重功能所致。较少
英文摘要
The t (3 ; 21) (q26 ; q22) translocation, which is one of consistent chromosomal abnormalities found in blastic crisis of chronic myelocytic leukemia (CML) , is thought to play an important role in leukemic progression of CML to an acute blastic crisis phase. The AML1 gene, which is located at the translocation breakpoint of the t (8 ; 21) (q22 ; q22) translocation found in acute myelocytic leukemia, was also rearranged by the t (3 ; 21) (q26 ; q22) translocation. Screening of a cDNA library of the t (3 ; 21) -carrying leukemic cell line cells (SKH1) resulted in the isolation of AML1/EVI-1 chimeric cDNAs. SKH1 cells expressed the 180 Kd AML1-EVI-1 fusion protein containing an amino-terminal half of AML1 including a runt homology domain which is fused to the entire of zinc finger EVI-1 protein. These findings strongly suggest that the t (3 ; 21) translocation results in the formation of a new class of a chimeric transcription factor which could contribute to leukemic progression of CML … More through interference with cell growth and differentiation. Biochemical analyzes revealed that AML1/EVI-1 itself does not alter the transactivation level through PEBP2 sites but dominantly suppresses the transactivation by intact AML1, which is assumed to be a stimulator of myeloid cell differentiation. The DNA-binding competition is a putative mechanism of such dominant negative effects of AML1/EVI-1 because it binds to PEBP2 sites in the higher affinity than AML1. Furthermore, AML1/EVI-1 stimulated the c-fos promoter transactivation and raised the AP-1 activity. Experiments, using deletion mutants of AML1/EVI-1, showed that these two functions are mutually independent because the dominant negative effects upon intact AML1 and the stimulation of AP-1 activity are dependent on the runt domain and the zinc finger domain near the C-terminus, respectively. Furthermore we showed that AML1/EVI-1 blocks granulocytic differentiation, otherwise induced by G-CSF,of 32Dc13 myeloid cells. It was also suggested that both AML1-derived and EVI-1-derived portions of the fusion protein play crucial roles for such differentiation block. We conclude that the leukemic cell transformation in t (3 ; 21) leukemias is probably caused by those dual functions of AML1/EVI-1 chimeric protein. Less
期刊论文(60)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Mitani K: "Generation of the AML1/Evi-1 fusion gene in the t(3:21)(q26;q22)causes blastic crisis in chronic myelocytic leukemia." EMBO J.13. 504-510 (1994)
Mitani K:“t(3:21)(q26;q22) 中 AML1/Evi-1 融合基因的产生会导致慢性粒细胞白血病的急变期。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Harada H,Kondo T,Ogawa S,Tamura T,Kitagawa M,Tanaka N,Lamphier MS,Hirai H.: "Taniguchi T.Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia ; A possible mechanism of tumor suppressor inactivation." Oncogene. 9. 3313-3320 (1994)
原田 H、近藤 T、小川 S、田村 T、北川 M、田中 N、兰菲尔 MS、平井 H.:“Taniguchi T.人类骨髓增生异常/白血病中 IRF-1 mRNA 的加速外显子跳跃;肿瘤抑制因子失活的可能机制
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Ogawa S: "Homozygous loss of the cyclin-dependent kinase 4-inhibitor(p16)gene in human leukemias." Blood. 84. 2431-2435 (1994)
Okawa S:“人类白血病中细胞周期蛋白依赖性激酶 4 抑制剂 (p16) 基因的纯合性缺失。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Tanaka T,Nishida J,Mitani K,Yazaki Y,Hirai H.: "Evi-1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain." J.Biol.Chem.269. 24020-24026 (1994)
Tanaka T、Nishida J、Mitani K、Yazaki Y、Hirai H.:“Evi-1 提高 AP-1 活性并刺激 c-fos 启动子反式激活,依赖于第二个锌指结构域。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Tanaka T: "Evi-1 raoses AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain." J.Biol.Chem. 269. 24020-24026 (1994)
Tanaka T:“Evi-1 提高 AP-1 活性并刺激 c-fos 启动子反式激活,依赖于第二个锌指结构域。”
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 26 条
Analyses of Maltipotential Functions of a Novel Signaling Molecule, Cas
-
批准号:11694250
-
项目类别:Grant-in-Aid for Scientific Research (A).
-
资助金额:$5.57万
-
财政年份:1999
-
负责人:HIRAI Hisamaru
-
依托单位:
Practical development of a novel method for hematopoietic stem cell expansion
-
批准号:09357010
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$18.24万
-
财政年份:1997
-
负责人:HIRAI Hisamaru
-
依托单位:
Analyses of a Novel Signaling Molecule, Cas
-
批准号:09044271
-
项目类别:Grant-in-Aid for international Scientific Research
-
资助金额:$5.44万
-
财政年份:1997
-
负责人:HIRAI Hisamaru
-
依托单位:
Analysis of molecular mechanisms of leukemia development
-
批准号:09307021
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$24.58万
-
财政年份:1997
-
负责人:HIRAI Hisamaru
-
依托单位:
Analysis of Molecular Mechanism of Blastic Crisis in Chronic Myelocytic Leukemia
-
批准号:07042002
-
项目类别:Grant-in-Aid for international Scientific Research
-
资助金额:$3.65万
-
财政年份:1995
-
负责人:HIRAI Hisamaru
-
依托单位:
Functional analysis of AML1 gene in normal hematopoietic cells and leukemia cells
-
批准号:07457229
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$4.48万
-
财政年份:1995
-
负责人:HIRAI Hisamaru
-
依托单位:
Molecular Diagnosis of Human Leukemias
-
批准号:04253208
-
项目类别:Grant-in-Aid for Scientific Research on Priority Areas
-
资助金额:$12.16万
-
财政年份:1992
-
负责人:HIRAI Hisamaru
-
依托单位:
Development and clinical application of molecular diagnosis in leukemias
-
批准号:04557133
-
项目类别:Grant-in-Aid for Developmental Scientific Research (B)
-
资助金额:$9.73万
-
财政年份:1992
-
负责人:HIRAI Hisamaru
-
依托单位:
Analysis of signal transduction mechanism through a novel tyrosine kinase receptor
-
批准号:03454521
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$3.9万
-
财政年份:1991
-
负责人:HIRAI Hisamaru
-
依托单位:
海外基金